 |
5 Diseases |  |
0 Trials |
|
0 Trials |  |
11 News |  |
- | CUDC-427 / Curis, Roche, xevinapant (AT-406) / Ascenta, EMD Serono
Journal: IAP antagonist GDC-0917 is more potent than Debio1143 in promoting cell death, c-IAP1 degradation and tumor growth inhibition. (Pubmed Central) - Oct 6, 2022
No abstract available
- | CUDC-427 / Curis, Roche
Clinical, P1 data, PK/PD data, Journal: A PHASE I DOSE ESCALATION STUDY EVALUATING THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF CUDC-427, A POTENT, ORAL, MONOVALENT IAP ANTAGONIST, IN PATIENTS WITH REFRACTORY SOLID TUMORS. (Pubmed Central) - Jan 14, 2018
The absence of severe toxicities, inhibition of cIAP-1 in PBMC, and antitumor activity warrant further studies. Clin Cancer Res; 22(18); 4567-73.
- CUDC-427 / Curis, Roche
Enrollment change, Trial termination, Trial primary completion date, Metastases: Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - Dec 1, 2016
P1, N=23, Terminated, Sponsor: Curis, Inc.
Clin Cancer Res; 22(18); 4567-73. N=36 --> 23 | Recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Mar 2015
- CUDC-427 / Curis, Roche
Trial primary completion date, Metastases: Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - Aug 21, 2015
P1, N=36, Recruiting, Sponsor: Curis, Inc.
N=36 --> 23 | Recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Mar 2015 Trial primary completion date: May 2015 --> Oct 2015
- CUDC-427 / Curis, Roche
Trial primary completion date, Metastases: Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - Jun 3, 2014
P1, N=36, Recruiting, Sponsor: Curis, Inc.
Trial primary completion date: May 2015 --> Oct 2015 Trial primary completion date: Jul 2014 --> May 2015
- CUDC-427 / Curis, Roche
Enrollment open, Metastases: Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - Jun 3, 2014
P1, N=36, Recruiting, Sponsor: Curis, Inc.
Trial primary completion date: Jul 2014 --> May 2015 Active, not recruiting --> Recruiting
- CUDC-427 / Curis, Roche
Enrollment closed, Metastases: Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - Nov 6, 2013
P1, N=36, Active, not recruiting, Sponsor: Curis, Inc.
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- | CUDC-427 / Curis, Roche
New P1 trial, Metastases: Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - Jul 23, 2013
P1, N=36, Active, not recruiting, Sponsor: Curis, Inc.
- | CUDC-427 / Curis, Roche
Trial completion: A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - Oct 29, 2012
P1, N=42, Completed, Sponsor: Genentech
Recruiting --> Active, not recruiting Recruiting --> Completed